CTVA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Corteva Inc (CTVA) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some positive technical indicators and moderate growth potential, the lack of significant positive catalysts, mixed analyst ratings, and recent financial performance suggest holding off on a purchase until clearer signals of growth or stability emerge.
The stock is showing bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram (0.168), and RSI_6 at 75.201 in the neutral zone. The stock is trading near its resistance level (R2: 83.546), indicating limited immediate upside potential. The overall trend is moderately bullish but lacks strong momentum.
The company has resolved litigation with Bayer, which is seen as a positive development. Analysts have raised price targets, with some firms maintaining Outperform or Buy ratings. The planned spin-off of the Seed and Crop Chemicals business could act as a future catalyst for re-rating.
Recent financials show a revenue decline of -1.71% YoY in Q4 2025, and while net income and EPS have improved, they remain negative. Analysts have downgraded the stock, citing valuation concerns and risks associated with the upcoming business split. The agriculture sector faces a choppy global backdrop, and crop protection sales estimates have deteriorated.
In Q4 2025, revenue dropped by -1.71% YoY to $3.91 billion. Net income improved significantly but remains negative at -$552 million. EPS increased to -0.82, up 1266.67% YoY. Gross margin improved to 38.29%, up 15.58% YoY, indicating some operational efficiency gains.
Analyst ratings are mixed. Price targets range from $77 to $89, with some firms maintaining Buy or Outperform ratings, while others have downgraded the stock to Neutral or Mixed. Concerns include valuation risks and execution challenges related to the planned business split.
